Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3,...
Hence then, the article about positive results from tezspire tezepelumab ekko phase 3 waypoint trial highlight rapid sustained effect in chronic rhinosinusitis with nasal polyps was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS )
Also on site :
- U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
- Goldfish Is Offering Fans Free Crackers for Tax Day—Here’s How To Claim Yours
- The Strange GLP-1 Side Effect Plaguing Patients Months After Starting